SCHEMBL19732368

SCHEMBL19732368

Cc1nc(-c2cc3n(n2)CCC3)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TGFB1 P01137 1/20 0.38
PDE10A Q9Y233 1/20 0.36
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19732370 0.85 TGFB1 (0.39) TGFB1PDE10AGRM5
SCHEMBL29832119 0.77 GRM5 (0.54) GRM5
SCHEMBL6100200 0.77 GRM5 (0.54) GRM5
SCHEMBL19732249 0.71 TGFBR1 (0.42)
SCHEMBL2524970 0.71 RAB9A (0.51)
SCHEMBL2525007 0.71 THRB (0.43)
SCHEMBL30139872 0.70 THRB (0.45) GRM5
SCHEMBL14844945 0.69 NISCH (0.38)
SCHEMBL29050018 0.68 GRM5 (0.53) GRM5
SCHEMBL29831821 0.68 GRM5 (0.53) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415341-B Benzotriazole-derived alpha, beta unsaturated amide compounds as TGF-beta R1 inhibitor 劲方医药科技(上海)有限公司 2021-02-26 CN disclosed
EP-3470409-B1 BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2020-02-12 EP disclosed
US-10548883-B2 Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2020-02-04 US disclosed
US-10548883-B2 Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2020-02-04 US disclosed
US-20190151299-A1 BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR GENFLEET THERAPEUTICS SHANGHAI INC. (CN) 2019-05-23 US disclosed
US-20190151299-A1 BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR GENFLEET THERAPEUTICS SHANGHAI INC. (CN) 2019-05-23 US disclosed
EP-3470409-A1 BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR Genfleet Therapeutics (Shanghai) Inc. (CN) 2019-04-17 EP disclosed
WO-2017215506-A1 BENZOTRIAZOLE-DERIVED Α AND Β UNSATURATED AMIDE COMPOUND USED AS TGF-ΒR1 INHIBITOR 南京明德新药研发股份有限公司 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10548883-B2 Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor TGFBR1, TGFBR2, TGFB1 TGFB1 3/4885PDE10A 3803/4885GRM5 1874/4885
US-20190151299-A1 BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR TGFBR1, TGFBR2, TGFB1 TGFB1 3/4885PDE10A 3736/4885GRM5 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.